These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays. Schwamborn K; Ammann JU; Knüchel R; Hartmann A; Baretton G; Lasitschka F; Schirmacher P; Braunschweig T; Tauber R; Erlmeier F; Hieke-Schulz S; Weichert W Virchows Arch; 2019 Nov; 475(5):599-608. PubMed ID: 31267201 [TBL] [Abstract][Full Text] [Related]
46. Intratumoral dendritic cells and T cells predict survival in gastroenteropancreatic neuroendocrine neoplasms. Werner W; Detjen K; Bruneau A; Lurje I; Nestel N; Jann H; Tacke F; Wiedenmann B; Roderburg C; Hammerich L Endocr Relat Cancer; 2023 Jul; 30(7):. PubMed ID: 37130269 [TBL] [Abstract][Full Text] [Related]
47. Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications. Fazio N; Milione M Cancer Treat Rev; 2016 Nov; 50():61-67. PubMed ID: 27636009 [TBL] [Abstract][Full Text] [Related]
48. Clinical significance of programmed cell death-ligand 1 expression and the immune microenvironment at the invasive front of colorectal cancers with high microsatellite instability. Korehisa S; Oki E; Iimori M; Nakaji Y; Shimokawa M; Saeki H; Okano S; Oda Y; Maehara Y Int J Cancer; 2018 Feb; 142(4):822-832. PubMed ID: 29044503 [TBL] [Abstract][Full Text] [Related]
49. Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor. Bösch F; Altendorf-Hofmann A; Jacob S; Auernhammer CJ; Spitzweg C; Boeck S; Schubert-Fritschle G; Werner J; Kirchner T; Angele MK; Knösel T J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33096620 [TBL] [Abstract][Full Text] [Related]
50. Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. Liao H; Chen W; Dai Y; Richardson JJ; Guo J; Yuan K; Zeng Y; Xie K Front Oncol; 2019; 9():883. PubMed ID: 31572677 [TBL] [Abstract][Full Text] [Related]
51. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma. Liu P; Xiao Q; Zhou B; Dai Z; Kang Y World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313 [TBL] [Abstract][Full Text] [Related]
52. Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors. Wang S; Liechty B; Patel S; Weber JS; Hollmann TJ; Snuderl M; Karajannis MA J Neurooncol; 2018 May; 138(1):183-190. PubMed ID: 29427150 [TBL] [Abstract][Full Text] [Related]
54. Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. Schoenfeld JD; Gjini E; Rodig SJ; Tishler RB; Rawal B; Catalano PJ; Uppaluri R; Haddad RI; Hanna GJ; Chau NG; Rabinowits G; Lorch J; Jo VY; Krane JF; Goguen LA; Annino DJ; Abdelrahman S; Lipschitz M; Margalit DN Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):137-145. PubMed ID: 29960819 [TBL] [Abstract][Full Text] [Related]
55. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. Prisciandaro M; Antista M; Raimondi A; Corti F; Morano F; Centonze G; Sabella G; Mangogna A; Randon G; Pagani F; Prinzi N; Niger M; Corallo S; Castiglioni di Caronno E; Massafra M; Bartolomeo MD; de Braud F; Milione M; Pusceddu S Front Oncol; 2022; 12():780716. PubMed ID: 35186729 [TBL] [Abstract][Full Text] [Related]
56. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma. Stenzel PJ; Schindeldecker M; Tagscherer KE; Foersch S; Herpel E; Hohenfellner M; Hatiboglu G; Alt J; Thomas C; Haferkamp A; Roth W; Macher-Goeppinger S Transl Oncol; 2020 Feb; 13(2):336-345. PubMed ID: 31881506 [TBL] [Abstract][Full Text] [Related]
58. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
59. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Vieira T; Antoine M; Hamard C; Fallet V; Duruisseaux M; Rabbe N; Rodenas A; Cadranel J; Wislez M Lung Cancer; 2016 Aug; 98():51-58. PubMed ID: 27393506 [TBL] [Abstract][Full Text] [Related]
60. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified. Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]